Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential.
Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential.
复制标题
来自低度恶性潜能卵巢肿瘤的肿瘤浸润淋巴细胞。
DOI：
10.1097/00004347-199301000-00006
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Whiteside,TL
中科院分区：
文献类型：
--
作者：
Vaccarello,L;Kanbour,A;Kanbour-Shakir,A;Whiteside,TL
通过免疫组织学原位研究来自人低度恶性潜能卵巢肿瘤（LMP）的肿瘤浸润淋巴细胞（TIL），并在从肿瘤中分离后进行功能表征。与卵巢癌相比，交界性（LMP）卵巢肿瘤含有明显较少的浸润白细胞。从表型上看，来自 LMP 肿瘤的 TIL 比来自卵巢癌的新鲜 TIL 含有明显更少的活化（HLA-DR+ 或 CD25+）淋巴细胞。此外，LMP 中 CD3-CD56+ 自然杀伤细胞的百分比高于卵巢癌。从 LMP 肿瘤获得的 TIL 在白细胞介素 2 (IL2) 和肿瘤坏死因子 α (TNFa) 存在的情况下在体外增殖良好，但没有显示出卵巢癌 TIL 中通常观察到的 CD3+ CD8+ T 淋巴细胞的选择性富集。来自 LMP 肿瘤的培养 TIL 对一组肿瘤细胞靶标的抗肿瘤细胞毒性与自体外周血淋巴细胞产生的效应细胞的抗肿瘤细胞毒性不同。然而，在 LMP 肿瘤的 TIL 长期培养物中，没有观察到针对自体肿瘤细胞的反应性显着富集。因此，浸润 LMP 肿瘤和浸润性卵巢癌的淋巴细胞的表型和功能特征之间观察到相当大的差异。
Tumor-infiltrating lymphocytes (TIL) from human ovarian tumors of low malignant potential (LMP) were studied in situ by immunohistology and characterized functionally after isolation from tumors. In comparison to ovarian carcinomas, borderline (LMP) ovarian tumors contained significantly fewer infiltrating leukocytes. Phenotypically, TIL from LMP tumors contained significantly fewer activated (HLA-DR+ or CD25+) lymphocytes than did fresh TIL from ovarian carcinomas. Also, percentages of CD3-CD56+ natural killer cells were higher in LMP than in ovarian carcinomas. TIL obtained from LMP tumors proliferated well in vitro in the presence of interleukin 2 (IL2) and tumor necrosis factor alpha (TNFa) but did not show a selective enrichment in CD3+ CD8+ T lymphocytes generally observed with TIL from ovarian carcinomas. Antitumor cytotoxicity against a panel of tumor cell targets of cultured TIL from LMP tumor did not parallel that of effectors generated from autologous peripheral blood lymphocytes. However, no significant enrichment in reactivity against autologous tumor cells was observed in long-term cultures of TIL from LMP tumors. Thus, considerable differences were observed between phenotypic and functional characteristics of lymphoid cells infiltrating LMP tumors and invasive ovarian carcinomas.